

# Ranjini K Sundaram

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11765956/publications.pdf>

Version: 2024-02-01

17  
papers

1,067  
citations

759233

12  
h-index

839539

18  
g-index

18  
all docs

18  
docs citations

18  
times ranked

2446  
citing authors

#	ARTICLE	IF	CITATIONS
1	2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	420
2	Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. <i>Nature Genetics</i> , 2018, 50, 1086-1092.	21.4	152
3	SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. <i>Cell Reports</i> , 2017, 20, 1921-1935.	6.4	147
4	PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. <i>Nature Communications</i> , 2019, 10, 3790.	12.8	54
5	Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors. <i>Cancer Research</i> , 2019, 79, 4331-4338.	0.9	44
6	Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay. <i>Journal of the American Chemical Society</i> , 2016, 138, 3844-3855.	13.7	43
7	Biodegradable PEG-poly( $\epsilon$ -pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors. <i>Biomaterials</i> , 2018, 178, 193-203.	11.4	43
8	Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 326-342.	4.1	36
9	Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity. <i>Translational Oncology</i> , 2021, 14, 101147.	3.7	28
10	Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1456-1469.	4.1	26
11	Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors. <i>NAR Cancer</i> , 2021, 3, zcab018.	3.1	17
12	Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity. <i>NAR Cancer</i> , 2021, 3, zcab021.	3.1	16
13	Development of a novel method to create double-strand break repair fingerprints using next-generation sequencing. <i>DNA Repair</i> , 2015, 26, 44-53.	2.8	14
14	TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1090-1102.	4.1	13
15	Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma. <i>Scientific Reports</i> , 2022, 12, 5827.	3.3	9
16	Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14664-e14664.	1.6	2
17	Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore. <i>Oncotarget</i> , 2021, 12, 891-906.	1.8	1